within Pharmacolibrary.Drugs.ATC.G;

model G04CA04
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.32,
    Cl             = 10.8 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 8 / 1000000,
    adminCount     = 1,
    Vd             = 0.0495,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.006733333333333333,
    Tlag           = 15.0
  );

  annotation(Documentation(
    info ="<html><body><p>Silodosin is a selective alpha-1 adrenergic receptor antagonist used primarily to treat the symptoms of benign prostatic hyperplasia (BPH) in adult men. It is an approved medication and works by relaxing muscles in the prostate and bladder neck, making it easier to urinate.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics reported in healthy adult male volunteers after a single oral dose.</p><h4>References</h4><ol><li><p>Matsubara, Y, et al., &amp; Midgley, I (2006). [Pharmacokinetics and disposition of silodosin (KMD-3213)]. <i>Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan</i> 126 Spec no. 237–245. DOI:<a href=&quot;https://doi.org/10.1248/yakushi.126.237&quot;>10.1248/yakushi.126.237</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/16518089/&quot;>https://pubmed.ncbi.nlm.nih.gov/16518089</a></p></li><li><p>Wang, Z, et al., &amp; Zhou, Y (2013). The influence of UGT2B7, UGT1A8, MDR1, ALDH, ADH, CYP3A4 and CYP3A5 genetic polymorphisms on the pharmacokinetics of silodosin in healthy Chinese volunteers. <i>Drug metabolism and pharmacokinetics</i> 28(3) 239–243. DOI:<a href=&quot;https://doi.org/10.2133/dmpk.dmpk-12-rg-106&quot;>10.2133/dmpk.dmpk-12-rg-106</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/23257391/&quot;>https://pubmed.ncbi.nlm.nih.gov/23257391</a></p></li><li><p>Sánchez Gómez, E, &amp; Arco Prados, Y (2014). [Review of pharmacological interactions of oral anticancer drugs provided at pharmacy department]. <i>Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria</i> 38(4) 338–363. DOI:<a href=&quot;https://doi.org/10.7399/fh.2014.38.4.1157&quot;>10.7399/fh.2014.38.4.1157</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/25137168/&quot;>https://pubmed.ncbi.nlm.nih.gov/25137168</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end G04CA04;
